Skip to Content

Clinical Trials Search Results

Showing 1-10 of 23

Sorted By:

  • A081105

    Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

  • ACCRU RU011201I

    A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.

  • Alliance A031201

    Phrase III trial of Enzalutamide versus Enzalutamide, Abiraterone, and Prednisone for Castration Resistant Metastatic Prostate Cancer

  • Alliance A151216

    Genetic Testing For Patients with Resectable or Resected Lung Cancer

  • Amgen 20120171

    Prospective, Observational Study to Determine Physician-assessed Clinical Considerations for Packed Red Blood Cell Transfusions in Subjects with Hemoglobin > 7 g/dL and < 10 g/Dl

  • CA204143

    An expanded Access Program for Leotuzumab in Combination with Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

  • CALGB 80702

    A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

  • CTSU/ECOG E2810

    Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

  • D4191C00001 PACIFIC

    A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemo radiation Therapy.

  • ECOG E2112

    A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

Page of 3, showing trials 1-10 of 23

Also in this Section